Case Western Reserve School of Medicine Wins Prestigious NCI Sponsored Provocative Questions Grant
The $1.9 Million Research Grant Will Allow Investigators to Detect Tumors in the Earliest Stages of Formation
Article ID: 608916
Released: 14-Oct-2013 2:35 PM EDT
Source Newsroom: Case Western Reserve University
Newswise — The National Cancer Institute’s (NCI) new Provocative Questions research funding program has awarded a prestigious grant to researchers at the Case Comprehensive Cancer Center and Case Western Reserve University’s Schools of Medicine and Engineering to study tumor detection at the earliest stages of growth.
“We know that the best way to fight cancer is to find tumors when they are small and have not yet left their primary location,” said principal investigator Susann Brady-Kalnay, PhD, professor of molecular biology and microbiology at Case Western Reserve University. “Our unique approach uses molecular imaging agents that recognize tumors using conventional MR scanners. We envision that this technological advance will allow us to detect very early stage tumors using conventional MRI machines that currently exist at most major hospitals.”
“Now that we have received the grant, our hope is to translate our discoveries into clinical practice,” said Brady-Kalnay. “With this technology, the radiologist will be confident that the abnormality on an MRI is actually a malignant tumor. This will inform the surgeon where all the tumor cells are located in order to remove them, and then the oncologist will be able to monitor how well each individual patient is responding to a given chemotherapy or radiation treatment,” stated Brady-Kalnay.
CWRU was uniquely positioned to win the Provocative Questions grant because of the University’s expertise in building world-class interdisciplinary teams that function with a high level of collaboration and cooperation. This strong suit is evident in the Provocative Questions grant team which includes chemists, MRI physicists, radiologists, biomedical engineers and cancer biologists, winning the $1.9 million award.
“Dr. Brady-Kalnay’s novel approach is built on her discovery of an abnormal protein fragment on tumor cells that encourages their movement through tissue,” stated Stanton Gerson, MD, Asa and Patricia Shiverick- Jane Shiverick (Tripp) Professor of Hematological Oncology, director of the Case Comprehensive Cancer Center and director of the Seidman Cancer Center at UH Case Medical Center. “This is a key factor that starts the process of metastasis, the most devastating part of cancer growth. Finding these cells early, and pinpointing their location by MR is a phenomenal advancement in the field of cancer diagnosis,” noted Gerson.
The grant is part of the NCI’s Provocative Questions Project (http://provocativequestions.nci.nih.gov/), conceived by NCI Director Harold Varmus, MD, to challenge cancer researchers to provide answers for 24 perplexing questions in cancer research. In 2012, the NCI assembled a list of important questions to stimulate the research community to use multiple scientific disciplines, including clinical and laboratory science and epidemiology, in novel ways to investigate promising but neglected or unexplored areas of research. A Provocative Questions research project is charged with tackling broad questions in cancer biology and aims for a 5-10- year time frame for making significant progress.
The Case Western Reserve University grant is one of only 30 awarded nationwide by the NCI in 2013 and only one of two in Ohio. The research team will address the NCI’s fifth Provocative Question: “Can tumors be detected when they are two to three orders of magnitude smaller than those currently detected with in vivo imaging modalities?”
In addition to Brady-Kalnay, the research team includes Mark Griswold, PhD, professor of radiology; Vikas Gulani, assistant professor of radiology; Zheng-Rong Lu, PhD, the M. Frank and Margaret Domiter Rudy Professor of Biomedical Engineering; and David Wilson, the Robert J. Herbold Professor, Biomedical Engineering.
About Case Western Reserve University School of Medicine
Founded in 1843, Case Western Reserve University School of Medicine is the largest medical research institution in Ohio and is among the nation’s top medical schools for research funding from the National Institutes of Health. The School of Medicine is recognized throughout the international medical community for outstanding achievements in teaching. The School’s innovative and pioneering Western Reserve2 curriculum interweaves four themes--research and scholarship, clinical mastery, leadership, and civic professionalism--to prepare students for the practice of evidence-based medicine in the rapidly changing health care environment of the 21st century. Nine Nobel Laureates have been affiliated with the School of Medicine.
Annually, the School of Medicine trains more than 800 MD and MD/PhD students and ranks in the top 25 among U.S. research-oriented medical schools as designated by U.S. News & World Report’s “Guide to Graduate Education.”
The School of Medicine’s primary affiliate is University Hospitals Case Medical Center and is additionally affiliated with MetroHealth Medical Center, the Louis Stokes Cleveland Department of Veterans Affairs Medical Center, and the Cleveland Clinic, with which it established the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University in 2002. http://casemed.case.edu
About Case Comprehensive Cancer Center
Case Comprehensive Cancer Center is an NCI-designated Comprehensive Cancer Center located at Case Western Reserve University. The center, now in its 25th year of funding, integrates the cancer research activities of the largest biomedical research and health care institutions in Ohio – Case Western Reserve, University Hospitals (UH) Case Medical Center and the Cleveland Clinic. NCI-designated cancer centers are characterized by scientific excellence and the capability to integrate a diversity of research approaches to focus on the problem of cancer. It is led by Stanton Gerson, MD, Asa and Patricia Shiverick- Jane Shiverick (Tripp) Professor of Hematological Oncology, director of the National Center for Regenerative Medicine, Case Western Reserve, and director of the Seidman Cancer Center at UH Case Medical Center.